Calendario›REGN›REGN5713

REGN5713

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Ensayo de REGENERON PHARMACEUTICALS, INC. en Conjuntivitis alergica.

Más ensayos de: Conjuntivitis alérgica.

Fase

Fase 3

Estado

Interrumpido

Participantes

24

previstos

Centros

2

Fin del objetivo primario

may 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ene 2026.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor Decision».

Qué mide

Ocular itch score in participants receiving REGN5713-5715 compared to placebo (At Day 8 post-Conjunctival Allergen Challenge (CAC)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe and effective the study drugs are at lowering eye allergy signs and symptoms compared with placebo. The study will also evaluate whether the combination (REGN5713-5715) has different effectiveness than REGN5713 or REGN5715 alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of the study drugs is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07309432), actualizada en ago 2026.